GI
PDLI

Gradient Investments’s PDL BioPharma, Inc. PDLI Stock Holding History

Gradient Investments’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-263
Closed -$1K – 1325
2019
Q3 		$1K Buy
+263
New +$703 ﹤0.01% 1092

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gradient Investments's PDLI Position: Q4 2019 in Review

Gradient Investments sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 263 shares — an estimated $1K sold.

Gradient Investments first reported a position in PDLI in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • Gradient Investments reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Gradient Investments sold 263 PDL BioPharma, Inc. shares in Q4 2019, an estimated $1K.
  • Gradient Investments first reported a position in PDL BioPharma, Inc. in Q3 2019 and held it in 1 quarter.
  • Gradient Investments's PDL BioPharma, Inc. position peaked at $1K in Q3 2019.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Gradient Investments's 13F filing for Q4 2019, filed 15 Jan 2020.